Maintenance Therapy With Selinexor and Azacitidine in TP53 Mutant AML/MDS After Transplantation
Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2028-12-30
Target enrollment:
Participant gender:
Summary
This study aims to explore the safety and efficacy of selinexor combined with azacitidine for maintenance therapy in TP53 mutant AML/MDS patients following transplantation.